| Product Type | Impurity Standards |
| CAT. No. | MRL-V07001 |
| CAS. No. | 1257044-40-8 |
| Mol. Formula | C45H50ClN7O7S |
| Mol. Weight | 868.45 |
| Synonyms | NA |
| Chemical Name | 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
| HSN Code | 38229010 |
| Country of Origin | India |
| Stock Status | Custom Synthesis |
Venetoclax is a BCL-2 inhibitor prescribed for the treatment of certain blood cancers, notably chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Operating by inhibiting the B-cell lymphoma-2 (BCL-2) protein, Venetoclax disrupts the survival mechanisms of cancer cells, triggering programmed cell death. It is often utilized in combination with other anti-cancer drugs, particularly in cases where the cancer cells exhibit the 17p deletion genetic abnormality, making them less responsive to standard treatments. The use of Venetoclax is carefully managed by healthcare professionals to ensure its efficacy and monitor potential side effects throughout the treatment course. Buy high quality Venetoclax from Molsyns Research. Molsyns Research is one of the leading manufacturer and exporter of Venetoclax